-
Tumors with TRK fusions (MSK, 2019): Tumors with TRK fusions based on MSK-IMPACT targeted sequencing.
- Description
This dataset contains summary data visualizations and clinical data from a broad sampling of tropomyosin receptor kinase (TRK) fusion tumors. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), information about mutated genes, patient demographics, and modality. The data set also...
- Subject
-
DNA Mutational AnalysisOncogene Proteins, FusionReceptor Protein-Tyrosine KinasesReceptor, trkAReceptor, trkBReceptor, trkC
- Access Rights
- Free to All
-
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
- Authors
- Burman, BharatJain, SwatiFitzgerald, Conall W.R.Sherman, Eric J.22 more author(s)...
- Description
Description from Zenodo: "This is a de-identified dataset accompanying the Nature Medicine publication titled "Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial", by Vos et al. (DOI: https://doi.org/10.1038/s41591-023-02518-x). It contains the clinical features and processed data of 64 patients with salivary gland cancer, treated with nivolumab and ipilimumab immunotherapy....
- Subject
-
Clinical Trial, Phase IIImmunotherapyIpilimumabNivolumabSalivary Gland Neoplasms
- Access Rights
- Free to All
-
Determinants of Response to Nivolumab plus Ipilimumab in a Phase II Trial of Advanced Salivary Gland Cancer Patients
- Description
Description from BioProject: "Salivary gland cancers (SGCs) are rare, aggressive cancers that lack effective treatments in the metastatic setting. We report the clinical results and immunogenomic correlates of response from a phase II trial evaluating nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) in metastatic SGC patients."
- Subject
-
Clinical Trial, Phase IIExome SequencingIpilimumabNivolumabRNA-SeqSalivary Gland Neoplasms
- Access Rights
- Free to All